Mirae Asset Global Etfs Holdings Ltd. Biotechnology

Mirae Asset Global Etfs Holdings Ltd.

$56.2 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$111B	$65 Million 0.12% of portfolio	165,945	Q3 2025 Reduced 24.38%
REGN Regeneron Pharmaceuticals, Inc.	$74.3B	$51.4 Million 0.09% of portfolio	91,383	Q3 2025 Added 13.69%
RPRX Royalty Pharma PLC	$17.1B	$9.22 Million 0.02% of portfolio	261,294	Q3 2025 Added 1,591.33%
CRSP Crispr Therapeutics Ag	$4.32B	$6.43 Million 0.01% of portfolio	99,204	Q3 2025 Reduced 5.88%
RNA Avidity Biosciences, Inc.	$3.69B	$5.34 Million 0.01% of portfolio	122,599	Q3 2025 Reduced 10.71%
MDGL Madrigal Pharmaceuticals, Inc.	$9.05B	$5.21 Million 0.01% of portfolio	11,356	Q3 2025 Reduced 9.07%
ALNY Alnylam Pharmaceuticals, Inc.	$55.3B	$4.87 Million 0.01% of portfolio	10,671	Q3 2025 Reduced 7.67%
ARWR Arrowhead Pharmaceuticals, Inc.	$4.37B	$4.76 Million 0.01% of portfolio	138,020	Q3 2025 Reduced 8.76%
INCY Incyte Corp	$23.2B	$4.25 Million 0.01% of portfolio	50,122	Q3 2025 Reduced 13.03%

BBIO Bridge Bio Pharma, Inc.	$9.84B	$4.18 Million 0.01% of portfolio	80,416	Q3 2025 Reduced 15.64%
JAZZ Jazz Pharmaceuticals PLC	$8.84B	$4.18 Million 0.01% of portfolio	31,689	Q3 2025 Reduced 38.02%
VCYT Veracyte, Inc.	$2.82B	$3.38 Million 0.01% of portfolio	98,587	Q3 2025 Reduced 7.68%
PTCT Ptc Therapeutics, Inc.	$5.39B	$3.35 Million 0.01% of portfolio	54,592	Q3 2025 Reduced 9.39%
CYTK Cytokinetics Inc	$6.25B	$3.27 Million 0.01% of portfolio	59,492	Q3 2025 Reduced 17.73%
MRNA Moderna, Inc.	$9.69B	$3.01 Million 0.01% of portfolio	116,638	Q3 2025 Reduced 4.32%
TECH Bio Techne Corp	$2.33B	$2.88 Million 0.01% of portfolio	51,787	Q3 2025 Reduced 2.87%
TGTX Tg Therapeutics, Inc.	$4.5B	$2.83 Million 0.01% of portfolio	78,319	Q3 2025 Reduced 11.81%
UTHR United Therapeutics Corp	$21.2B	$2.75 Million 0.0% of portfolio	6,559	Q3 2025 Added 1.2%

RYTM Rhythm Pharmaceuticals, Inc.	$5.54B	$2.74 Million 0.0% of portfolio	27,122	Q3 2025 Reduced 16.16%
NUVL Nuvalent, Inc.	$4.15B	$2.68 Million 0.0% of portfolio	30,967	Q3 2025 Reduced 8.92%
BEAM Beam Therapeutics Inc.	$1.55B	$2.64 Million 0.0% of portfolio	108,681	Q3 2025 Reduced 7.46%
KRYS Krystal Biotech, Inc.	$5.29B	$2.35 Million 0.0% of portfolio	13,290	Q3 2025 Reduced 13.04%
AXSM Axsome Therapeutics, Inc.	$5.99B	$2.28 Million 0.0% of portfolio	18,802	Q3 2025 Reduced 15.24%
PCVX Vaxcyte, Inc.	$2.87B	$2.19 Million 0.0% of portfolio	60,828	Q3 2025 Reduced 21.0%
BMRN Biomarin Pharmaceutical Inc	$10.2B	$2.19 Million 0.0% of portfolio	40,409	Q3 2025 Reduced 5.0%
QURE Uni Qure N.V.	$1.4B	$2.18 Million 0.0% of portfolio	37,289	Q3 2025 Added 0.2%
NTLA Intellia Therapeutics, Inc.	$661M	$2.08 Million 0.0% of portfolio	120,415	Q3 2025 Reduced 7.02%
PTGX Protagonist Therapeutics, Inc	$4.15B	$2.05 Million 0.0% of portfolio	30,871	Q3 2025 Reduced 13.87%
LEGN Legend Biotech Corp	$5.07B	$1.96 Million 0.0% of portfolio	60,178	Q3 2025 Reduced 2.37%
DNLI Denali Therapeutics Inc.	$2.34B	$1.89 Million 0.0% of portfolio	129,887	Q3 2025 Reduced 3.58%
RARE Ultragenyx Pharmaceutical Inc.	$2.32B	$1.88 Million 0.0% of portfolio	62,603	Q3 2025 Added 3.9%
AKRO Akero Therapeutics, Inc.	$2.52B	$1.86 Million 0.0% of portfolio	39,276	Q3 2025 Reduced 8.36%
ADMA Adma Biologics, Inc.	$3.06B	$1.85 Million 0.0% of portfolio	125,919	Q3 2025 Reduced 10.1%
ARQT Arcutis Biotherapeutics, Inc.	$1.5B	$1.8 Million 0.0% of portfolio	95,625	Q3 2025 Added 44.37%
BNTX Bio N Tech Se	$25B	$1.75 Million 0.0% of portfolio	17,746	Q3 2025 Reduced 2.73%
CRNX Crinetics Pharmaceuticals, Inc.	$2.34B	$1.75 Million 0.0% of portfolio	42,009	Q3 2025 Reduced 22.2%
ACAD Acadia Pharmaceuticals Inc	$3.89B	$1.7 Million 0.0% of portfolio	79,741	Q3 2025 Reduced 6.38%
SRRK Scholar Rock Holding Corp	$1.95B	$1.67 Million 0.0% of portfolio	44,805	Q3 2025 Reduced 9.26%
LGND Ligand Pharmaceuticals Inc	$3.39B	$1.57 Million 0.0% of portfolio	8,869	Q3 2025 Reduced 15.18%
KYMR Kymera Therapeutics, Inc.	$3.55B	$1.52 Million 0.0% of portfolio	26,918	Q3 2025 Reduced 2.51%
ACLX Arcellx, Inc.	$3.94B	$1.51 Million 0.0% of portfolio	18,402	Q3 2025 Reduced 19.35%
MIRM Mirum Pharmaceuticals, Inc.	$2.63B	$1.5 Million 0.0% of portfolio	20,444	Q3 2025 Reduced 20.28%
AGIO Agios Pharmaceuticals, Inc.	$2.39B	$1.47 Million 0.0% of portfolio	36,592	Q3 2025 Reduced 7.55%
XENE Xenon Pharmaceuticals Inc.	$2.54B	$1.42 Million 0.0% of portfolio	35,301	Q3 2025 Reduced 15.24%
CPRX Catalyst Pharmaceuticals, Inc.	$2.38B	$1.22 Million 0.0% of portfolio	61,817	Q3 2025 Reduced 9.34%
EXEL Exelixis, Inc.	$13.4B	$1.2 Million 0.0% of portfolio	28,992	Q3 2025 Reduced 21.42%
STOK Stoke Therapeutics, Inc.	$1.05B	$1.19 Million 0.0% of portfolio	50,463	Q3 2025 Reduced 5.52%
FOLD Amicus Therapeutics, Inc.	$2.66B	$1.17 Million 0.0% of portfolio	148,727	Q3 2025 Reduced 43.88%
IDYA Ideaya Biosciences, Inc.	$1.54B	$1.14 Million 0.0% of portfolio	42,077	Q3 2025 Reduced 17.95%
BGNE Bei Gene, Ltd.	$23.5B	$1.1 Million 0.0% of portfolio	4,869	Q3 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Etfs Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Etfs Holdings Ltd. with notifications on news.